YD Bio Limited Warrants closed at $0.71 on Sep 28, up 23.83%, 69.1% below its highest close since Aug 29. Volume of 168.6K shares was 14.40× its 20-day average (well above normal).
Split-adjusted performance: +102.8% over one month, +5.2% over six months.
Short interest was 66.0K shares at the Sep 15 settlement (16.8 days to cover).
No reported quarters with price history yet.
Not enough peers to rank
No recent articles focused on YD Bio Limited Warrants. 3 articles mention it in passing.
YD Bio Ltd is a biotechnology company focused on regulated diagnostics, life science clinical services and healthcare product commercialization. Its operations include DNA methylation-based oncology testing programs in the United States under an LDT framework with CLIA-certified and CAP-accredited laboratory partners. The Company also provides life science distribution and clinical trial supply chain services, including procurement, logistics coordination and compliance-focused support for clinical development programs. It maintains ocular health product commercialization operations in the United States and consumer healthcare distribution activities in Asia. The Company operates in the United States and Taiwan, with Taiwan generating maximum revenue.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
